Cough in Idiopathic Pulmonary Fibrosis Market Positioned for Robust Growth Through 2034, DelveInsight Finds

The Cough in Idiopathic Pulmonary Fibrosis (IPF) market was valued at approximately USD 154 million in 2022 and is projected to grow at a significant CAGR during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the cough in IPF landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The cough in IPF market is increasingly driven by unmet medical needs and growing patient demand for symptom relief. The recently approved nerandomilast (JASCAYD) by Boehringer Ingelheim represents a landmark development, being the first new therapy approved for IPF in over a decade, and highlights the significant therapeutic potential within this space.

Cough in Idiopathic Pulmonary Fibrosis Epidemiology

In 2022, the total diagnosed prevalent cases of cough in Idiopathic Pulmonary Fibrosis in the 7MM (the United States, EU4 countries including Germany, France, Italy, and Spain, the United Kingdom, and Japan) were nearly 148,000 cases. The United States reported the highest diagnosed prevalent cases with more than 76,000 cases.

The Cough in Idiopathic Pulmonary Fibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Cough in Idiopathic Pulmonary Fibrosis Market Size
• Cough in Idiopathic Pulmonary Fibrosis Market Size by Therapies
• Cough in Idiopathic Pulmonary Fibrosis Market Size by Class

According to estimates, the total diagnosed prevalent cases of cough in IPF in the 7MM were expected to increase by 2034 due to improved awareness, aging populations, and advancements in diagnostic capabilities. For more information, visit Cough in Idiopathic Pulmonary Fibrosis Epidemiology Analysis.

Cough in Idiopathic Pulmonary Fibrosis Overview

Cough in Idiopathic Pulmonary Fibrosis represents a significant and often debilitating symptom in patients living with IPF, a rare and progressive disorder characterized by scarring in the walls of the air sacs in the lungs. IPF is most commonly diagnosed in patients aged 60 to 70 years and is characterized by progressive lung function decline. Persistent, dry cough is a hallmark symptom of the disease, severely impacting patients' quality of life and overall well-being. The disease causes significant economic burden on patients and healthcare systems, disrupting patients' overall well-being and quality of life. The cause of IPF remains unknown, though it is associated with risk factors including age, smoking history, and genetic predisposition.

Key Trends in Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market:

• Approval of Targeted P2X3 Antagonists: Emerging therapies like gefapixant and other P2X3 receptor antagonists showing efficacy in reducing cough frequency and severity
• Neuromodulator Development: Increased focus on neuromodulator-based approaches and sensory nerve inhibitors targeting cough pathophysiology
• Combination Therapy Approaches: Development of combination regimens pairing symptom-relief agents with existing antifibrotic therapies
• Improved Patient Understanding: Enhanced awareness among healthcare professionals and patients about the importance of early diagnosis and management of IPF-related cough
• Biomarker-Driven Treatment Selection: Growing adoption of patient-specific treatment approaches based on cough phenotype and response patterns
• Digital Health Integration: Use of remote patient monitoring and digital tools to track symptom progression and treatment response

For more Cough in Idiopathic Pulmonary Fibrosis market insights, download our report.

Recent Development In The Cough in IPF Treatment Landscape:

• In November 2025, CHEST 2025 presented CORAL Phase 2b results: nalbuphine ER reduced cough frequency by up to 60% in IPF patients, with benefits from week 2.
• In October 2025, the U.S. Food and Drug Administration approved Boehringer Ingelheim's nerandomilast (Jascayd) for the treatment of adults with idiopathic pulmonary fibrosis (IPF), marking the first new therapy approved for IPF in over 10 years. Nerandomilast, an oral phosphodiesterase 4B (PDE4B) inhibitor, demonstrated statistically significant efficacy in slowing the rate of lung function decline in the Phase III FIBRONEER-IPF clinical trial.
• In August 2025, Pulmonary Fibrosis Foundation reported Phase 2b CORAL trial positive results for nalbuphine ER in reducing chronic cough frequency in IPF; Trevi plans Phase 3 in H1 2026.
• In July 2025, the FDA approved Jascayd (nerandomilast) tablets by Boehringer Ingelheim as the first new IPF treatment in over a decade, targeting lung function decline.
• In June 2025, Trevi Therapeutics announced positive topline results from Phase 2b CORAL trial of nalbuphine ER (Haduvio), achieving primary endpoint with statistically significant reductions in 24-hour cough frequency across all doses in IPF patients with chronic cough.

Cough in Idiopathic Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cough in Idiopathic Pulmonary Fibrosis market or expected to get launched during the study period. The analysis covers Cough in Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cough in Idiopathic Pulmonary Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cough in Idiopathic Pulmonary Fibrosis Therapies and Key Companies

• Jascayd (nerandomilast): Boehringer Ingelheim
• BLU-5937: Bellus Health
• Gefapixant: Merck
• ME-015: Melius Pharma
• Investigational agents from Trevi Therapeutics, Algernon Pharmaceuticals and others.

To know more about Cough in Idiopathic Pulmonary Fibrosis companies working in the treatment market, visit @ Cough in Idiopathic Pulmonary Fibrosis Clinical Trials and Therapeutic Assessment

Cough in Idiopathic Pulmonary Fibrosis Market Drivers

• Increasing prevalence of IPF globally, particularly among aging populations
• Growing patient demand for symptom-relief therapies addressing unmet medical needs
• Improved understanding of cough pathophysiology in IPF and development of targeted approaches
• Rising awareness among healthcare professionals and patients about early diagnosis and management importance
• Significant economic burden of IPF-related cough driving healthcare expenditure
• Advancements in diagnostic capabilities and molecular understanding of disease mechanisms
• Development of combination therapies improving patient outcomes and quality of life

Cough in Idiopathic Pulmonary Fibrosis Market Barriers

• Complex mechanisms behind IPF-related cough complicating drug development
• Lack of validated endpoints for clinical trials in cough assessment
• Difficulty in measuring treatment effectiveness objectively
• Regulatory hurdles and lengthy approval processes for rare disease therapies
• High costs associated with developing novel drugs for rare conditions
• Failures and discontinuation of emerging therapies affecting market momentum
• Unaffordable pricing limiting patient access and market growth
• Market access and reimbursement issues in different geographic regions
• Shortage of healthcare specialists specializing in pulmonary fibrosis
• Undiagnosed and unreported cases affecting true disease prevalence estimation
• Limited awareness about the disease among general population and healthcare providers

Scope of the Cough in Idiopathic Pulmonary Fibrosis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Cough in Idiopathic Pulmonary Fibrosis Companies: Boehringer Ingelheim, Bellus Health, Merck, Melius Pharma, Trevi Therapeutics, Algernon Pharmaceuticals, and others
• Key Cough in Idiopathic Pulmonary Fibrosis Therapies: Jascayd (nerandomilast), BLU-5937, Gefapixant, ME-015, and other investigational agents
• Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and emerging therapies
• Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, Market entry strategies
• Cough in Idiopathic Pulmonary Fibrosis Unmet Needs, KOL's views, Analyst's views, Cough in Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

Discover more about therapies set to grab major Cough in Idiopathic Pulmonary Fibrosis market share @ Cough in Idiopathic Pulmonary Fibrosis Treatment Market